Novo Nordisk's newest Victoza campaign doubles down on its approved trifecta of preventative indications for heart attack, stroke and CV death.

Lilly and BI are gunning for a heart-failure nod for Jardiance. And they want to be able to talk up the drug’s effects on exercise ability, too.

Another Rare Disease Day, another rare-disease marketing campaign from Cambridge BioMarketing. This time, the agency has launched a podcast series.

Trogarzo (ibalizumab-uiyk) is the first HIV therapy with a novel mechanism of action in more than 10 years.

BMS has longevity and strong data on its side when it comes to staying on top of the immuno-oncology field. But a convenience boost can’t hurt.

CSL’s new brand positioning is actually its first—and it comes after more than 100 years in business.

Disconnects still exist in perceptions around migraines.

Will pharma creativity get a push from Cannes Lions Health? The festival has drawn lines between the pharma and health and wellness categories.